Dendreon, the Seattle-based maker of immune-boosting therapies for cancer, said today it has started a mid-stage clinical trial of Provenge for patients with localized prostate cancer who are about to have their prostates surgically removed. The trial, called NeoACT, will enroll about 40 patients at the University of California San Francisco. That study will be getting underway as the company (NASDAQ: [[ticker:DNDN]]) awaits big news in the coming months from a trial of 500 men that will examine whether Provenge can extend lives when used against more advanced forms of prostate cancer.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
